

# Conference Program

Wednesday, January 7

---

6:00 p.m.-7:00 p.m.

**OPENING SESSION/WELCOME/KEYNOTE PRESENTATION**

*Aventine DEFG*

**MYC functions within a transcriptional regulatory network**

Robert N. Eisenman, Fred Hutchinson Cancer Research Center, Seattle, WA

7:00 p.m.-9:00 p.m.

**OPENING RECEPTION**

*Vicino Ballroom*

Thursday, January 8

---

7:00 a.m.-8:00 a.m.

**BREAKFAST**

*Grand Foyer*

8:00 a.m.-10:00 a.m.

**PLENARY SESSION 1: MYC IN HUMAN CANCERS**

Session Chairperson: Christine M. Eischen, Vanderbilt University, Nashville, TN

*Aventine DEFG*

**Dissection of the BRG1 and MYC/MAX biological connection and its use in lung cancer therapeutics**

Montserrat Sanchez-Cespedes, Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain

**Role of MYC in germinal-center development and in lymphomagenesis**

Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, NY

**Neuroblastoma as a paradigm of MYC(N) driven cancers**

John M. Maris, The Children's Hospital of Philadelphia, PA

**Long noncoding RNA PVT1 potentiates MYC in human cancers with 8q24 gain\***

Anindya Bagchi, University of Minnesota, Minneapolis, MN

**Dynamic epigenetic regulation of glioblastoma tumorigenicity through a LSD1-MYC-OLIG2 axis\***

Clark Chen, University of California, San Diego, La Jolla, CA

10:00 a.m.-10:30 a.m.

**BREAK**

*Grand Foyer*

\*Short talks from proffered papers.

MYC: FROM BIOLOGY TO THERAPY

10:30 a.m.-12:30 p.m.

**PLENARY SESSION 2: MYC AND METABOLISM/METABOLOMICS**

Session Chairperson: Javier León, Instituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain  
*Aventine DEFG*

**Targeting MYC-mediated cancer metabolism**

Chi Van Dang, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

**Recycling Myc to survive stress**

Maralice Conacci-Sorrell, Fred Hutchinson Cancer Research Center, Seattle, WA

**Metabolic reprogramming by MYC: Lessons learned from adenovirus**

Heather R. Christofk, UCLA School of Medicine, Los Angeles, CA

**MYC and mitochondrial metabolism in childhood neuroblastoma**

Marie Arsenian-Henriksson, Karolinska Institutet, Stockholm, Sweden

*There will be no short talks in this session.*

12:30 p.m.-2:30 p.m.

**LUNCH ON OWN**

2:30 p.m.-4:30 p.m.

**PLENARY SESSION 3: MYC FUNCTION AND PHOSPHORYLATION/UBIQUITINATION**

Session Chairperson: Lars-Gunnar Larsson, Karolinska Institutet, Stockholm, Sweden  
*Aventine DEFG*

**Dynamic regulation of MYC and MYCN ubiquitination**

Iannis Aifantis, Howard Hughes Medical Institute/NYU School of Medicine, New York, NY

**Post-translational regulation of MYC's oncogenic activity**

Rosalie C. Sears, Oregon Health & Science University, Portland, OR

**Control of mitochondrial transcription by MYC is essential for the survival of MYC-transformed cells**

Steven B. McMahon, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA

**Serine 62 phosphorylated MYC associates with nuclear lamins and its regulation by CIP2A is essential for proliferation induction in vivo\***

Jukka Westermarck, Centre for Biotechnology and Department of Pathology, University of Turku, Turku, Finland

**Drugging MYC proteins through amphosteric inhibition of Aurora kinase A\***

W. Clay Gustafson, University of California, San Francisco, CA

\*Short talks from proffered papers.

4:30 p.m.-7:00 p.m.

**POSTER SESSION A with RECEPTION**

*Vicino Ballroom*

**Friday, January 9**

---

7:00 a.m.-8:00 a.m.

**BREAKFAST**

*Grand Foyer*

8:00 a.m.-10:00 a.m.

**PLENARY SESSION 4: MODELING MYC IN MOUSE**

Session Chairperson: Louis Chesler, Institute of Cancer Research, Sutton, United Kingdom

*Aventine DEFG*

**Mechanisms of MYC addiction**

Dean W. Felsher, Stanford University School of Medicine, Stanford, CA

**Modeling MYCN-driven tumors in human stem cells**

William A. Weiss, University of California, San Francisco, CA

**Investigating Myc function in mouse model of carcinogenesis**

Owen J. Sansom, Beatson Institute for Cancer Research, Glasgow, UK

**The MYC-MIZ1 interaction defines tumor identity**

Martine F. Roussel, St. Jude Children's Research Hospital, Memphis, TN

*There will be no short talks in this session.*

10:00 a.m.-10:30 a.m.

**BREAK**

*Grand Foyer*

\*Short talks from proffered papers.

10:30 a.m.-12:30 p.m.

**PLENARY SESSION 5: MYC-DEPENDENT TRANSCRIPTION: AMPLIFICATION VERSUS GENE-SPECIFIC MODELS**

Session Chairperson: Charles Lin, Dana-Farber Cancer Institute, Boston, MA  
*Aventine DEFG*

**Transcriptional regulation by physiological and oncogenic Myc levels**

Martin Eilers, University of Würzburg, Würzburg, Germany

**Control theory of MYC function and expression**

David L. Levens, National Cancer Institute, Bethesda, MD

**“Amplification versus Gene-Specific Models”: What is this session about?**

Bruno Amati, Italian Institute of Technology and European Institute of Oncology, Milan, Italy

**Targeting of CDK7 inhibits super-enhancer-associated oncogenic programs in MYCN-amplified tumor cells\***

Edmond Chipumuro, Dana-Farber Cancer Institute, Boston, MA

**Oncogenic MYC induces a dependency on mRNA processing in human breast cancer\***

Thomas F. Westbrook, Baylor College of Medicine, Houston, TX

12:30 p.m.-3:00 p.m.

**POSTER SESSION B with LUNCH**

*Vicino Ballroom*

3:00 p.m.-5:00 p.m.

**PLENARY SESSION 6: MYC AND EMERGING BIOLOGY**

Session Chairperson: John M. Sedivy, Brown University, Providence, RI  
*Aventine DEFG*

**Mechanisms of MYC-driven genomic instability**

Jean J. Gautier, Columbia University, New York, NY

**Reduced expression of MYC increases longevity and enhances healthspan**

John M. Sedivy, Brown University, Providence, RI

**The MYC-microRNA pathway in B-cell neoplasms**

Andrei Thomas-Tikhonenko, The Children’s Hospital of Philadelphia, PA

**MYC-dependent translation makes an impact: Tailor-made protein expression for cancer development\***

Davide Ruggero, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

**The N-MYC transcriptional program driving the neuroendocrine prostate cancer phenotype\***

David Rickman, Weill Cornell Medical College, New York, NY

\*Short talks from proffered papers.

5:15 p.m.-6:30 p.m.

**SHORT TALKS ON TARGETING MYC-DRIVEN CANCERS**

Session Chairperson: Laura Soucek, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

*Aventine DEFG*

**Facilitates Chromatin Transcription (FACT) acts in a forward feedback loop with MYCN and is a therapeutic target in neuroblastoma\***

Daniel R. Carter, Children's Cancer Institute, Lowy Cancer Centre, University of New South Wales, Randwick, Australia

**Preclinical validation of Myc inhibition by a new generation of Omomyc-based cell penetrating peptides\***

Laura Soucek, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

**Cross-cancer evaluation of MYC synthetic lethal targets in The Cancer Genome Atlas\***

Brady Bernard, Institute for Systems Biology, Seattle, WA

**Selective targeting of MYC mRNA by chemically stabilized antisense oligonucleotides\***

Christopher J. Ott, Dana-Farber Cancer Institute, Boston, MA

**miR-17-92 mediates MYC oncogene addiction\***

Yulin Li, Stanford University, Stanford, CA

**EVENING OFF/DINNER ON OWN**

\*Short talks from proffered papers.

Saturday, January 10

---

7:00 a.m.-8:00 a.m.

**BREAKFAST**

*Grand Foyer*

8:00 a.m.-10:00 a.m.

**PLENARY SESSION 7: MYC BEYOND CANCER**

Session Chairperson: Laura A. Johnston, Columbia University Medical Center, New York, NY

*Aventine DEFG*

**MYC is not required for the maintenance of pluripotency, but controls the balance between cellular metabolic activity and dormancy in ESCs and pre-implantation embryos**

Andreas Trumpp, German Cancer Research Center, Heidelberg, Germany

**An ancient signaling mechanism mediates the response of cells to fitness differences arising during tissue growth**

Laura A. Johnston, Columbia University Medical Center, New York, NY

**MYC in germinal center B cell physiology and pathology**

Dinis Calado, London Research Institute, London, UK

**HIF-2alpha regulates self-renewal of MYC dependent cancer stem cells\***

Bikul Das, Stanford University School of Medicine, Stanford, CA

**ERK2 binds to MYC promoter and induces MYC expression\***

Javier León, Instituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain

10:00 a.m.-10:30 a.m.

**BREAK**

*Grand Foyer*

10:30 a.m.-11:15 a.m.

**KEYNOTE PRESENTATION**

*Aventine DEFG*

**Title to be announced**

Peter K. Vogt, The Scripps Research Institute, La Jolla, CA

**11:15 a.m.-12:45 p.m.**

**PLENARY SESSION 8: THERAPEUTIC TRANSLATION**

Session Chairperson: Marie Arsenian-Henriksson, Karolinska Institutet,  
Stockholm, Sweden  
*Aventine DEFG*

**Targeting MYC to kill cancers, not patients**

Gerard I. Evan, University of Cambridge, Cambridge, UK

**Overcoming complexity: Targeting common vulnerabilities of MYC-driven cancers**

Carla Grandori, Fred Hutchinson Cancer Research Center, Seattle, WA

**Inhibition of MYC transcriptional signaling**

James E. Bradner, Dana-Farber Cancer Institute, Boston, MA

*There will be no short talks in this session.*

**12:45 p.m.-1:00 p.m.**

**CLOSING REMARKS/DEPARTURE**